On this page

hydrocortisone valerate cream

Prescription ANDA TE AB Official labelling
Informational index, not medical advice. Content is reproduced from public FDA and NLM data. Always confirm against the manufacturer's current prescribing information. Report adverse events to FDA MedWatch.

Overview

Brand name
hydrocortisone valerate cream
Generic name
hydrocortisone valerate cream
Dosage form
Cream
Route
Topical
Marketing category
ANDA · ANDA
Labeler
Bryant Ranch Prepack
Product type
Human Prescription Drug
DEA schedule
Not scheduled
Active ingredients
1
NDC product codes
4
Packages
7
Data completeness
76% of corroborating sources present

Active ingredients

Source: NDC Directory
Active ingredients and strengths as listed in the NDC Directory.
Ingredient Strength RxCUI Monograph
Hydrocortisone Valerate 2 mg/g 1370754 View

Forms, strengths and routes

Source: NDC Directory
Dosage form
Cream
Route of administration
Topical
Presentations
11

Pharmacologic classes are listed in the class section below.

Pharmacologic class

Source: NDC Directory
Established pharmacologic classes (EPC), mechanisms of action (MoA), chemical structures (CS) and physiologic effects (PE).
Class Type Browse
Corticosteroid Hormone Receptor Agonists [MoA] MoA All 215 members
Corticosteroid [EPC] EPC All 215 members

Regulatory status

Source: Drugs@FDANDC Directory
Application number
211047
Application type
ANDA · Abbreviated New Drug Application
Approval date
November 4, 2021
Sponsor
ENCUBE ETHICALS
Products on application
1
Submissions recorded
1
Products approved under application 211047.
Product Trade name Form Strength Ingredient Status TE Flags
211047-001 HYDROCORTISONE VALERATE CREAM HYDROCORTISONE VALERATE Prescription AB

Therapeutic equivalence

Source: Orange Book
TE code
AB
Reference Listed Drug
No
Reference Standard
No

What this rating means: Therapeutically equivalent — bioequivalence demonstrated by in vivo or in vitro testing

Codes beginning with “A” indicate products the FDA considers therapeutically equivalent. Codes beginning with “B” indicate bioequivalence has not been established. See methodology.

Approval history

Source: Drugs@FDA
Most recent submissions on application 211047.
Type No. Action Status Date Review
Original application 1 Approved November 4, 2021 Standard

Prescribing information

Source: openFDA Drug Labeling

Reproduced verbatim from the Structured Product Labeling submitted to the FDA (effective 20251022). This is the manufacturer's labelling text, not a summary and not advice.

HUMAN PRESCRIPTION DRUG · 20251022 HUMAN PRESCRIPTION DRUG · 20250909

Indications and Usage

openFDA Drug Labeling

INDICATIONS AND USAGE Hydrocortisone valerate cream USP, 0.2% is medium potency corticosteroids indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses in adult patients.

Dosage and Administration

openFDA Drug Labeling

DOSAGE AND ADMINISTRATION Hydrocortisone valerate cream USP, 0.2% should be applied to the affected area as a thin film two or three times daily depending on the severity of the condition. As with other corticosteroids, therapy should be discontinued when control is achieved. If no improvement is seen within 2 weeks, reassessment of the diagnosis may be necessary. Hydrocortisone valerate cream USP, 0.2% should not be used with occlusive dressings unless directed by a physician. Hydrocortisone valerate cream USP, 0.2% should not be applied in the diaper area if the patient requires diapers or plastic pants as these garments may constitute occlusive dressing.

Contraindications

openFDA Drug Labeling

CONTRAINDICATIONS Hydrocortisone valerate cream USP, 0.2% is contraindicated in those patients with a history of hypersensitivity to any of the components of the preparations.

Adverse Reactions

openFDA Drug Labeling

ADVERSE REACTIONS Hydrocortisone Valerate Cream USP, 0.2% The following local adverse reactions have been reported with topical corticosteroids, and they may occur more frequently with the use of occlusive dressings. These reactions are listed in an approximate decreasing order of occurrence: burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae, and miliaria. In controlled clinical studies involving pediatric patients one month to 2 years of age (n=29), the incidence of adverse experiences, regardless of relationship to the use of hydrocortisone valerate cream USP, 0.2%, was approximately 21%. Reported reactions included stinging (10%), eczema (7%), fungal infection (3%), and gastrointestinal disorder (3%). In controlled clinical studies involving pediatric patients 2 to 12 years of age (n=153), the incidence of adverse experiences, regardless of relationship to the use of hydrocortisone valerate cream USP, 0.2%, was approximately 10%. Reported reactions included stinging (3%), burning skin (2%), infection (Body as a Whole) (2%). Skin irritation, eczema, pruritus, application site reaction, rash, rash maculopapular, and dry skin were all reported at incidences of approximately 1%. To report SUSPECTED ADVERSE REACTIONS , contact Encube Ethicals Private Limited al 1-833-285-4151 or FDA at 1-800-FDA- 1088 or www.fda.gov/medwatch.

Description

openFDA Drug Labeling

DESCRIPTION Hydrocortisone valerate cream USP, 0.2% contain hydrocortisone valerate, 11,21-dihydroxy-17-[(1-oxopentyl)oxy]-(11β)-pregn-4-ene-3,20-dione, a synthetic corticosteroid for topical dermatologic use. The corticosteroids constitute a class of primarily synthetic steroids used topically as anti-inflammatory and antipruritic agents. Chemically, hydrocortisone valerate is C 26 H 38 O 6 . It has the following structural formula: Hydrocortisone valerate has a molecular weight of 446.58. It is a white, crystalline solid, soluble in ethanol and methanol, sparingly soluble in propylene glycol and insoluble in water. Each gram of hydrocortisone valerate cream USP, 0.2% contains 2 mg hydrocortisone valerate in a hydrophilic base composed of carbomer homopolymer type C, dibasic sodium phosphate, methylparaben, sodium lauryl sulfate, polyoxyethylene (100) stearyl ether, stearyl alcohol, white petrolatum, polyoxyl 2 stearyl ether, purified water and propylene glycol. hv-image.jpg

OVERDOSAGE Topically applied hydrocortisone valerate cream USP, 0.2% can be absorbed in sufficient amounts to produce systemic effects (see PRECAUTIONS ).

How Supplied / Storage and Handling

openFDA Drug Labeling

HOW SUPPLIED Hydrocortisone valerate cream USP, 0.2%, is supplied in 15 g (NDC 21922-007-04), 45g (NDC 21922-007-06), 60 g (NDC 21922-007-07) tube sizes. STORAGE Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Made in France, formulated in India. Mfg. Lic. No. 361 Manufactured by: Encube Ethicals Pvt. Ltd. Plot No. C1, Madkaim Industrial Estate, Madkaim, Post Mardol, Ponda, Goa-403 404, India. Distributed by: Encube Ethicals Inc. 200 Meredith Avenue, Suite 202 Durham, NC 27713 USA Rev 04 Rev. 12/23

Adverse event reports

Source: openFDA FAERS
614
FAERS reports mentioning this drug
as of 2026-09-25T03:42:24+00:00
A report count is not a risk measure. FAERS accepts voluntary and mandatory reports without establishing causation, and reporting is influenced by how widely a drug is used, how long it has been marketed, and media attention. FDA states that reports “do not prove that the drug caused the event”. Compare rates, not totals.

Attributed to this product's most-reported active ingredient: HYDROCORTISONE VALERATE. Combination products with more than six active ingredients are not attributed, because a report count summed across a long ingredient list measures the list, not the medicine.

Packaging and NDCs

Source: NDC Directory
Every National Drug Code package associated with this medication. The NDC is the identifier used for dispensing, billing and pharmacovigilance in the United States.
Package NDC Product NDC Labeler Description Marketing start
71335-2723-1 71335-2723 Bryant Ranch Prepack 1 TUBE in 1 CARTON (71335-2723-1) / 60 g in 1 TUBE July 29, 2025
71335-2843-1 71335-2843 Bryant Ranch Prepack 1 TUBE in 1 CARTON (71335-2843-1) / 15 g in 1 TUBE October 22, 2025
72162-2301-4 72162-2301 Bryant Ranch Prepack 1 TUBE in 1 CARTON (72162-2301-4) / 45 g in 1 TUBE December 31, 2022
72162-2301-6 72162-2301 Bryant Ranch Prepack 1 TUBE in 1 CARTON (72162-2301-6) / 60 g in 1 TUBE December 31, 2022
21922-007-04 21922-007 Encube Ethicals, Inc. 1 TUBE in 1 CARTON (21922-007-04) / 15 g in 1 TUBE December 31, 2022
21922-007-06 21922-007 Encube Ethicals, Inc. 1 TUBE in 1 CARTON (21922-007-06) / 45 g in 1 TUBE December 31, 2022
21922-007-07 21922-007 Encube Ethicals, Inc. 1 TUBE in 1 CARTON (21922-007-07) / 60 g in 1 TUBE December 31, 2022
71335-2723 71335-2723 Bryant Ranch Prepack — December 31, 2022
71335-2843 71335-2843 Bryant Ranch Prepack — December 31, 2022
72162-2301 72162-2301 Bryant Ranch Prepack — December 31, 2022
21922-007 21922-007 Encube Ethicals, Inc. — December 31, 2022

Sources for this page

Every dataset that contributed a fact to this page.
Dataset Agency Used for
NDC Directory FDA Identity, ingredients, strengths, forms, routes, labelers, packages
Drugs@FDA FDA Application, sponsor, submissions, review documents, marketing status
Orange Book FDA Therapeutic equivalence codes, reference drug flags, patents, exclusivity
Drug Labeling FDA / NLM Prescribing information reproduced above
FAERS FDA Adverse event report counts

Generated September 25, 2026 · 11 sections on this page.